Pyridoxamine reduces post-injury fibrosis and improves functional recovery after acute kidney injury.

Pyridoxamine reduces post-injury fibrosis and improves functional recovery after acute kidney injury. Am J Physiol Renal Physiol. 2016 May 18;:ajprenal.00056.2016 Authors: Skrypnyk NI, Voziyan P, Yang H, de Caestecker CR, Theberge MC, Drouin M, Hudson B, Harris RC, de Caestecker MP Abstract Acute kidney injury (AKI) is a common and independent risk factor for death and chronic kidney disease (CKD). Despite promising preclinical data, there is no evidence that anti-oxidants reduce the severity of injury, increase recovery, or prevent CKD in patients with AKI. Pyridoxamine (PM) is a structural analog of vitamin B6 that interferes with oxidative macromolecular damage via a number of different mechanisms, and is in a phase 3 clinical efficacy trial to delay CKD progression in patients with diabetic kidney disease. Since oxidative stress is implicated as one of the main drivers of renal injury after AKI, the ability of PM to interfere with multiple aspects of oxidative damage may be favorable for AKI treatment. In these studies we therefore evaluated PM treatment in a mouse model of AKI. Pretreatment with PM caused a dose-dependent reduction in acute tubular injury, long-term post-injury fibrosis, as well as improved functional recovery after ischemia-reperfusion AKI (IR-AKI). This was associated with a dose-dependent reduction in oxidative stress marker isofuran/F2-isoprostane ratio, indicating that PM reduces renal oxidative damage post...
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research